1. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. (28th February 2013) Authors: Barbaud, A.; Collet, E.; Milpied, B.; Assier, H.; Staumont, D.; Avenel‐Audran, M.; Grange, A.; Amarger, S.; Girardin, P.; Guinnepain, M.‐T.; Truchetet, F.; Lasek, A.; Waton, J. Journal: British journal of dermatology Issue: Volume 168:Number 3(2013:Mar.) Page Start: 555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cross‐reactivity in beta‐lactams after a non‐immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions. (28th October 2019) Authors: Bérot, V.; Gener, G.; Ingen‐Housz‐Oro, S.; Gaudin, O.; Paul, M.; Chosidow, O.; Wolkenstein, P.; Assier, H. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 4(2020) Page Start: 787 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cutaneous tests and interest of iobitridol in non‐immediate hypersensitivity to contrast media: a case series of 43 patients. (6th January 2020) Authors: Gaudin, O.; Deschamps, O.; Duong, T. A.; Gener, G.; Paul, M.; Luciani, A.; Chosidow, O.; Wolkenstein, P.; Ingen‐Housz‐Oro, S.; Assier, H. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 4(2020) Page Start: e178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Most chilblains observed during the COVID‐19 outbreak occur in patients who are negative for COVID‐19 on polymerase chain reaction and serology testing. (1st November 2020) Authors: Le Cleach, L.; Dousset, L.; Assier, H.; Fourati, S.; Barbarot, S.; Boulard, C.; Bourseau Quetier, C.; Cambon, L.; Cazanave, C; Colin, A.; Kostrzewa, E.; Lesort, C.; Levy Roy, A.; Lombart, F.; Marco‐Bonnet, J.; Monfort, J.‐B.; Samimi, M.; Tardieu, M.; Wolkenstein, P.; Sbidian, E. Journal: British journal of dermatology Issue: Volume 183:Number 5(2020) Page Start: 866 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Most chilblains observed during the COVID‐19 outbreak occur in patients who are negative for COVID‐19 on polymerase chain reaction and serology testing. (9th August 2020) Authors: Le Cleach, L.; Dousset, L.; Assier, H.; Fourati, S.; Barbarot, S.; Boulard, C.; Bourseau Quetier, C.; Cambon, L.; Cazanave, C; Colin, A.; Kostrzewa, E.; Lesort, C.; Levy Roy, A.; Lombart, F.; Marco‐Bonnet, J.; Monfort, J.‐B.; Samimi, M.; Tardieu, M.; Wolkenstein, P.; Sbidian, E. Journal: British journal of dermatology Issue: Volume 183:Number 5(2020) Page Start: 866 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Non‐acral skin manifestations during the COVID‐19 epidemic: COVIDSKIN study by the French Society of Dermatology. (12th May 2021) Authors: Guelimi, R.; Salle, R.; Dousset, L.; Assier, H.; Fourati, S.; Bhujoo, Z.; Barbarot, S.; Boulard, C.; Cazanave, C.; Colin, A.; Kostrzewa, E.; Lesort, C.; Levy Roy, A.; Lombart, F.; Marco Bonnet, J.; Marty, L.; Monfort, J.B.; Riffaud, L.; Samimi, M.; Tardieu, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 9(2021) Page Start: e539 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin and pristinamycin: clinical history and patch testing. (1st October 2018) Authors: El Khoury, M.; Assier, H.; Gener, G.; Paul, M.; Haddad, C.; Chosidow, O.; Wolkenstein, P.; Ingen‐Housz‐Oro, S. Journal: British journal of dermatology Issue: Volume 179:Number 4(2018) Page Start: 978 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Valaciclovir: a culprit drug for drug reaction with eosinophilia and systemic symptoms not to be neglected. Three cases. (1st March 2019) Authors: Ingen‐Housz‐Oro, S.; Bernier, C.; Gener, G.; Fichel, F.; Barbaud, A.; Lebrun‐Vignes, B.; Assier, H. Journal: British journal of dermatology Issue: Volume 180:Number 3(2019) Page Start: 666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Valaciclovir: a culprit drug for drug reaction with eosinophilia and systemic symptoms not to be neglected. Three cases. (1st November 2018) Authors: Ingen‐Housz‐Oro, S.; Bernier, C.; Gener, G.; Fichel, F.; Barbaud, A.; Lebrun‐Vignes, B.; Assier, H. Journal: British journal of dermatology Issue: Volume 180:Number 3(2019) Page Start: 666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗